{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:38:16Z","timestamp":1785458296017,"version":"3.56.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1097\/md.0000000000001234","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T11:18:19Z","timestamp":1438168699000},"page":"e1234","source":"Crossref","is-referenced-by-count":8,"title":["Sustained Virologic Response to a Dual Peginterferon alfa-2a and Ribavirin in Treating Chronic hepatitis C Infection"],"prefix":"10.1097","volume":"94","author":[{"given":"Cho","family":"Naing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Than","family":"Sitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aye TD","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyan","family":"Aung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-23-20210226","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"R4-23-20210226","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"R5-23-20210226","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1756-0500-5-135","article-title":"The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients","volume":"5","author":"Nishikawa","year":"2012","journal-title":"BMC Res Notes"},{"key":"R7-23-20210226","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R8-23-20210226","doi-asserted-by":"crossref","first-page":"e112592","DOI":"10.1371\/journal.pone.0112592","article-title":"Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C","volume":"9","author":"Susser","year":"2014","journal-title":"PLoS One"},{"key":"R9-23-20210226","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/apt.12273","article-title":"Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy","volume":"37","author":"Koh","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-23-20210226","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1128\/JCM.39.4.1536-1539.2001","article-title":"Molecular characteristic-based epidemiology of hepatitis B, C, and E viruses and GB virus C\/hepatitis G virus in Myanmar","volume":"39","author":"Nakai","year":"2001","journal-title":"J Clin Microbiol"},{"key":"R11-23-20210226","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1440-1746.2007.04834.x","article-title":"Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients","volume":"22","author":"Kuboki","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R12-23-20210226","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"R13-23-20210226","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/ajg.2012.48","article-title":"Update on the management and treatment of hepatitis C virus infection: recommendations from the department of veterans affairs hepatitis c resource center program and the national hepatitis c program office","volume":"107","author":"Yee","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R14-23-20210226","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1016\/j.ijid.2012.03.012","article-title":"Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients","volume":"16","author":"Aziz","year":"2012","journal-title":"Int J Infect Dis"},{"key":"R15-23-20210226","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12072-010-9207-1","article-title":"Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C","volume":"4","author":"Pattullo","year":"2010","journal-title":"Hepatol Int"},{"key":"R16-23-20210226","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1016\/j.ijid.2013.05.012","article-title":"Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan","volume":"17","author":"Gill","year":"2013","journal-title":"Int J Infect Dis"},{"key":"R17-23-20210226","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","article-title":"Treatment of chronic hepatitis C in Asia: when East meets West","volume":"24","author":"Yu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"R18-23-20210226","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Bochud","year":"2009","journal-title":"J Hepatol"},{"key":"R19-23-20210226","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1002\/hep.1840360715","article-title":"Introduction to therapy of hepatitis C","volume":"36","author":"Lindsay","year":"2002","journal-title":"Hepatology (Baltimore, MD"},{"key":"R21-23-20210226","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology (Baltimore, MD"},{"key":"R22-23-20210226","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","article-title":"Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)\/ribavirin","volume":"43","author":"Ferenci","year":"2005","journal-title":"J Hepatol"},{"key":"R23-23-20210226","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1007\/s00705-014-2185-1","article-title":"Increased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004\u20132007 and 2008\u20132011","volume":"159","author":"Rong","year":"2014","journal-title":"Arch Virol"},{"key":"R24-23-20210226","doi-asserted-by":"crossref","first-page":"e0126764","DOI":"10.1371\/journal.pone.0126764","article-title":"Genotypic distribution of hepatitis C virus in Thailand and southeast Asia","volume":"10","author":"Wasitthankasem","year":"2015","journal-title":"PLoS One"},{"key":"R25-23-20210226","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.2002.009936","article-title":"Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis","volume":"53","author":"Castera","year":"2004","journal-title":"Gut"},{"key":"R26-23-20210226","first-page":"125","article-title":"Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C","volume":"52","author":"Castera","year":"2006","journal-title":"Minerva Gastroenterol Dietol"},{"key":"R27-23-20210226","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0168-8278(00)00036-2","article-title":"Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C","volume":"34","author":"Serfaty","year":"2001","journal-title":"J Hepatol"},{"key":"R28-23-20210226","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/gut.2005.069757","article-title":"Steatosis in chronic hepatitis C: why does it really matter?","volume":"55","author":"Asselah","year":"2006","journal-title":"Gut"},{"key":"R29-23-20210226","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/jgh.12329","article-title":"Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin","volume":"29","author":"Chen","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R30-23-20210226","doi-asserted-by":"crossref","first-page":"e0125400","DOI":"10.1371\/journal.pone.0125400","article-title":"Prevalence of tymine-adenine dinucleotide repeat, IL28B and IFNL4 in Thai population and correlation with spontaneous clearance and treatment outcome of hepatitis c infection","volume":"10","author":"Thong","year":"2015","journal-title":"PLoS One"},{"key":"R31-23-20210226","doi-asserted-by":"crossref","first-page":"e45698","DOI":"10.1371\/journal.pone.0045698","article-title":"Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis","volume":"7","author":"Jia","year":"2012","journal-title":"PLoS One"},{"key":"R32-23-20210226","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gutjnl-2012-302553","article-title":"Hepatitis C virus kinetics by administration of pegylated interferon-\u03b1 in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene","volume":"62","author":"Watanabe","year":"2013","journal-title":"Gut"},{"key":"R33-23-20210226","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jgh.12475","article-title":"Role of IL28B for chronic hepatitis C treatment toward personalized medicine","volume":"29","author":"Matsuura","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R34-23-20210226","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1665-2681(19)31735-1","article-title":"Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications","volume":"9 Suppl","author":"Arrese","year":"2010","journal-title":"Ann Hepatol"},{"key":"R35-23-20210226","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jhep.2008.12.017","article-title":"Insulin resistance predicts response to peginterferon-alpha\/ribavirin combination therapy in chronic hepatitis C patients","volume":"50","author":"Dai","year":"2009","journal-title":"J Hepatol"},{"key":"R36-23-20210226","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1365-2036.2011.04716.x","article-title":"Meta-analysis: insulin resistance and sustained virological response in hepatitis C","volume":"34","author":"Eslam","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-23-20210226","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/INF.0b013e318159836c","article-title":"Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection","volume":"27","author":"Jara","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R38-23-20210226","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/jhep.2000.7880","article-title":"Hepatitis C, interferon alfa, and depression","volume":"31","author":"Zdilar","year":"2000","journal-title":"Hepatology"},{"key":"R39-23-20210226","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"R40-23-20210226","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R41-23-20210226","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gut.2003.038257","article-title":"Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy","volume":"53","author":"Veldt","year":"2004","journal-title":"Gut"},{"key":"R42-23-20210226","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"R43-23-20210226","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2009.08.021","article-title":"A lymphotoxin-driven pathway to hepatocellular carcinoma","volume":"16","author":"Haybaeck","year":"2009","journal-title":"Cancer Cell"},{"key":"R44-23-20210226","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.26624","article-title":"Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon\/ribavirin obviates a protease inhibitor","volume":"59","author":"Pearlman","year":"2014","journal-title":"Hepatology"},{"key":"R45-23-20210226","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"Saarrazin","year":"2012","journal-title":"J Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T20:03:09Z","timestamp":1748548989000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201507050-00023"}},"subtitle":["A Retrospective Cohort Study"],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":41,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001234","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}